Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan M Dacek

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Frontiers in Oncology|October 12, 2020
CAR Chase: Where Do Engineered Cells Go in Humans?Simone Krebs, Megan M Dacek, Lukas M Carter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 4, 2021
Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejectionLeila Peraro, Christopher M Bourne, Megan M Dacek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic CancerKelly E Henry, Megan M Dacek, Thomas R Dilling, et al.
Cancer Immunology Research|September 22, 2019
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor ImmunopeptidomeClaire Y Oh, Martin G Klatt, Christopher Bourne, et al.
Cancers|August 9, 2020
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug DeliveryThomas J Gardner, Christopher M Bourne, Megan M Dacek, et al.
Blood|January 25, 2023
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blockerMegan M Dacek, Keifer G Kurtz, Patrick Wallisch, et al.
Cancer Immunology Research|June 28, 2023
Host Interactions with Engineered T-cell MicropharmaciesChristopher M Bourne, Patrick Wallisch, Megan M Dacek, et al.
Nature Chemical Biology|December 31, 2021
Engineering CAR-T cells to activate small-molecule drugs in situThomas J Gardner, J Peter Lee, Christopher M Bourne, et al.
Blood|April 15, 2022
A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignanciesMartin G Klatt, Tao Dao, Zhiyuan Yang, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Oncology|October 12, 2020
CAR Chase: Where Do Engineered Cells Go in Humans?Simone Krebs, Megan M Dacek, Lukas M Carter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 4, 2021
Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejectionLeila Peraro, Christopher M Bourne, Megan M Dacek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic CancerKelly E Henry, Megan M Dacek, Thomas R Dilling, et al.
Cancer Immunology Research|September 22, 2019
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor ImmunopeptidomeClaire Y Oh, Martin G Klatt, Christopher Bourne, et al.
Cancers|August 9, 2020
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug DeliveryThomas J Gardner, Christopher M Bourne, Megan M Dacek, et al.
Blood|January 25, 2023
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blockerMegan M Dacek, Keifer G Kurtz, Patrick Wallisch, et al.
Cancer Immunology Research|June 28, 2023
Host Interactions with Engineered T-cell MicropharmaciesChristopher M Bourne, Patrick Wallisch, Megan M Dacek, et al.
Nature Chemical Biology|December 31, 2021
Engineering CAR-T cells to activate small-molecule drugs in situThomas J Gardner, J Peter Lee, Christopher M Bourne, et al.
Blood|April 15, 2022
A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignanciesMartin G Klatt, Tao Dao, Zhiyuan Yang, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Pageof 2